95, 409–417 (1998).
53. Luczo, J. M. et al. Molecular pathogenesis of H5 highly pathogenic avian inﬂu-
enza: the role of the haemagglutinin cleavage site motif. Rev. Med Virol. 25,
406–430 (2015).
54. Boonstra, S. et al. Hemagglutinin-mediated membrane fusion: a biophysical
perspective. Annu Rev. Biophys. 47, 153–173 (2018).
55. McCraw, D. M., Gallagher, J. R. & Harris, A. K. Characterization of inﬂuenza vaccine
hemagglutinin complexes by cryo-electron microscopy and image analyses
reveals structural polymorphisms. Clin. Vaccin. Immunol. 23, 483–495 (2016).
56. Kost, T. A. & Condreay, J. P. Recombinant baculoviruses as expression vectors for
insect and mammalian cells. Curr. Opin. Biotechnol. 10, 428–433 (1999).
57. Webster, R. G., Brown, L. E. & Jackson, D. C. Changes in the antigenicity of the
hemagglutinin molecule of H3 inﬂuenza virus at acidic pH. Virology 126, 587–599
(1983).
58. Lee, P. S. & Wilson, I. A. Structural characterization of viral epitopes recognized by
broadly cross-reactive antibodies. Curr. Top. Microbiol. Immunol. 386, 323–341
(2015).
59. Turner, H. L. et al. Potent anti-inﬂuenza H7 human monoclonal antibody induces
separation of hemagglutinin receptor-binding head domains. PLoS Biol. 17,
e3000139 (2019).
60. Khurana, S. et al. Repeat vaccination reduces antibody afﬁnity maturation across
different inﬂuenza vaccine platforms in humans. Nat. Commun. 10, 3338 (2019).
61. Ekiert, D. C. et al. Antibody recognition of a highly conserved inﬂuenza virus
epitope. Science 324, 246–251 (2009).
62. Kallewaard, N. L. et al. Structure and function analysis of an antibody recognizing
all inﬂuenza A subtypes. Cell 166, 596–608 (2016).
63. Benhaim, M. A. et al. Structural monitoring of a transient intermediate in the
hemagglutinin fusion machinery on inﬂuenza virions. Sci. Adv. 6, eaaz8822 (2020).
64. Portnoff, A. D. et al. Inﬂuenza hemagglutinin nanoparticle vaccine elicits broadly
neutralizing antibodies against structurally distinct domains of H3N2 HA. Vaccines
8, 99 (2020).
65. Richards, K. A. et al. Recombinant HA-based vaccine outperforms split and sub-
unit vaccines in elicitation of inﬂuenza-speciﬁc CD4 T cells and CD4 T cell-
dependent antibody responses in humans. NPJ Vaccines 5, 77 (2020).
66. Tay, T. et al. Investigation into alternative testing methodologies for characteriza-
tion of inﬂuenza virus vaccine. Hum. Vaccines Immunother. 11, 1673–1684 (2015).
67. Gallagher, J. R. et al. Characterization of hemagglutinin antigens on inﬂuenza
virus and within vaccines using electron microscopy. Vaccines https://doi.org/
10.3390/vaccines6020031 (2018).
68. Public Health Agency of Canada. Oculo-respiratory syndrome following inﬂuenza
vaccination: review of post-marketing surveillance through four inﬂuenza sea-
sons in Canada. Can. Commun. Dis. Rep. 31, 217–225 (2005).
69. Choudhri, Y. & Walop, W. Inﬂuenza vaccine-associated adverse events: results of
passive surveillance, Canada 2001-2002. Can. Commun. Dis. Rep. 28, 189–196
(2002).
70. Babiuk, S. et al. Aggregate content inﬂuences the Th1/Th2 immune response to
inﬂuenza vaccine: evidence from a mouse model. J. Med. Virol. 72, 138–142 (2004).
71. Wei, C. J. et al. Cross-neutralization of 1918 and 2009 inﬂuenza viruses: role of
glycans in viral evolution and vaccine design. Sci. Transl. Med. 2, 24ra21 (2010).
72. An, Y. et al. N-glycosylation of seasonal inﬂuenza vaccine hemagglutinins:
implication for potency testing and immune processing. J Virol. https://doi.org/
10.1128/JVI.01693-18 (2019).